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Asymptomatic infections by Plasmodium falciparum 
were first considered to be a consequence of naturally 
acquired immunity (NAI) (Christophers 1924) and were 
later designated as premonition (Sergent & Parrot 1935). 
However, proof that NAI against the asexual blood stag-
es of P. falciparum was of immune origin was provided 
by Cohen et al. (1961) only after the cure of an acutely 
infected child by the passive transfer of immunoglobulin 
obtained from asymptomatic Gambian adults. NAI was 
later described by Bruce-Chwatt (1980) as a common 
phenomenon in African adults living in holoendemic ru-
ral areas of the southern Sahara. Epidemiological stud-
ies in Gambia (Greenwood et al. 1987) have shown that 
death due to malaria occurs predominantly in infants 
and young children despite the presence of Plasmodium 
parasites in the blood of all age groups. Detailed studies 
conducted in Dielmo, Senegal (Trape et al. 1994), more 
precisely identified the characteristics of clinical (anti-
disease) immunity and anti-parasite immunity in ho-
loendemic situations. First, clinical immunity to P. falci-
parum infection, which is principally observed in adults, 
protects against symptoms associated with malaria. 
Furthermore, this immunity may persist at high levels 
in clinically immune older children and adolescents in-
dependent of parasite density. Second, anti-parasite im-
munity develops progressively after adolescence and is 
characterised by a marked drop in the parasite density in 
infected young adults. Sterile immunity and total clini-
cal protection were never observed, but the incidence of 
clinical infections was 40 times higher in children (0-4 
years old) than in adults (Trape et al. 1994, Rogier et 
al. 1999a, b). The antibody-dependent anti-parasite im-
munity against asexual blood stages observed by Cohen 
et al. (1961) was later demonstrated not to be purely hu-
moral, but also dependent upon the activity of a cellular 
component. In experimental primate infections (Faun-
der et al. 1984, Groux et al. 1990) and in human antibody 
transfer experiments (Bouharoum-Tavoun et al. 1990), 
the in vitro and in vivo anti-parasite antibody activities 
did not correlate and the in vivo activity was restricted to 
isotype-specific antibodies, specifically IgG1 and IgG3 
in humans (Roussilhon et al. 2007) and cytophylic IgGs 
in Saimiri monkeys (Groux et al. 1990).
However, even though epidemiological studies in 
endemic areas have been performed, little is known re-
garding the clinical and anti-parasite NAI in infections 
with other human malaria parasites. Important and ex-
tensive studies (Collins & Jeffery 1999, 2004) based on 
a retrospective examination of sporozoite and tropho-
zoite-induced infections in patients with neurosyphilis 
who were treated with P. falciparum and Plasmodium 
vivax-based malaria therapy have provided some infor-
mation concerning the development of immunity to P. 
vivax. These studies demonstrated that P. vivax-infected 
patients were more sensitive to re-infection with heter-
Financial support: CNPq CT-Amazônia (575855/2008), FNS 
(761/2006), Furnas Centrais Elétricas SA 
+ Corresponding author: hildebrando@ipepatro.org.br
Received 17 October 2011
Accepted 2 February 2012 
Asymptomatic infection with 
Plasmodium falciparum and Plasmodium vivax 
in the Brazilian Amazon Basin: to treat or not to treat?
Mauro Shugiro Tada1, Ricardo de Godoi Mattos Ferreira2, Tony Hiroshi Katsuragawa2, 
Rosimeire Cristina Dalla Martha1, Joana D’Arc Neves Costa1, Letusa Albrecht3, 
Gerhard Wunderlich3, Luiz Hildebrando Pereira da Silva2/+
1Centro de Pesquisa em Medicina Tropical 2Instituto de Pesquisa em Patologias Tropicais, Porto Velho, RO, Brasil 
3Departamento de Parasitologia, Universidade de São Paulo, São Paulo, SP, Brasil
In this study, we determined whether the treatment of asymptomatic parasites carriers (APCs), which are fre-
quently found in the riverside localities of the Brazilian Amazon that are highly endemic for malaria, would decrease 
the local malaria incidence by decreasing the overall pool of parasites available to infect mosquitoes. In one village, 
the treatment of the 19 Plasmodium falciparum-infected APCs identified among the 270 residents led to a clear reduc-
tion (Z = -2.39, p = 0.017) in the incidence of clinical cases, suggesting that treatment of APCs is useful for control-
ling falciparum malaria. For vivax malaria, 120 APCs were identified among the 716 residents living in five villages. 
Comparing the monthly incidence of vivax malaria in two villages where the APCs were treated with the incidence in 
two villages where APCs were not treated yielded contradictory results and no clear differences in the incidence were 
observed (Z = -0.09, p = 0.933). Interestingly, a follow-up study showed that the frequency of clinical relapse in both 
the treated and untreated APCs was similar to the frequency seen in patients treated for primary clinical infections, 
thus indicating that vivax clinical immunity in the population is not species specific but only strain specific.
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ologous parasites than with P. falciparum, suggesting 
that at least in adults, NAI is more rapidly and efficiently 
acquired against P. falciparum.
Studies performed by our teams in Rondônia (RO), a 
state in the western Brazilian Amazon, showed that as-
ymptomatic infection with P. vivax occurs frequently in 
the riverside areas of the Madeira River (Camargo et al. 
1999). Detailed studies in the rural riverbank localities 
of the Madeira and Machado Rivers (Alves et al. 2002) 
showed that the overall prevalence of asymptomatic in-
fection with P. falciparum or P. vivax was four-five times 
higher than the corresponding prevalence of symptom-
atic infection: 20-4.5% in a locality of the Madeira River 
and 49.5% and 10% in the localities of the Machado, re-
spectively. In the latter localities, which consist of more 
dispersed and isolated human communities, equivalent 
frequencies of asymptomatic P. falciparum, P. vivax 
and mixed infections were observed (16.2%, 18% and 
15.3%, respectively). Furthermore, we found that the de-
velopment of NAI was related to the individual’s age and 
length of residence in the endemic riverside area where 
the Anopheles darlingi vector is present at a high density 
(Gil et al. 2003, Cruz et al. 2009). Epidemiological sur-
veys of the suburban and rural communities near the city 
of Porto Velho, the capital of RO (Fig. 1), also reported a 
relatively high prevalence of asymptomatic infections in 
the riverside areas (Gil et al. 2007, Tada et al. 2007, Kat-
suragawa et al. 2008, 2010). More detailed studies con-
ducted in rural communities in the vicinity of the urban 
area of Porto Velho showed that asymptomatic infections 
were limited to long-term residents. By contrast, clinical 
malaria cases from the area were more frequent in non-
residents on short stays for fishing or tourism who slept 
in tents or shacks that rendered them more susceptible to 
Anopheles bites (Katsuragawa et al. 2010).
The demonstration that asymptomatic parasite carriers 
(APC) can infect anopheline vectors (Alves et al. 2005) 
and the discovery of asymptomatic infections in other ar-
eas of the Amazon (Ladeia-Andrade et al. 2009) raised 
the question of the role of APCs in malaria transmission. 
Consequently, treatment of APCs may be important for 
improving malaria control campaigns. In the present 
study, we present preliminary trials examining whether 
the treatment of APCs in highly endemic communities 
may decrease the incidence of clinical cases or affect oth-
er aspects of malaria transmission within the locality.
SUBJECTS, MATERiALS AND METHoDS
Study area - The present study was performed in the 
following five suburban and rural riverbank localities of 
the Madeira River, situated to the south of the city of 
Porto Velho (Fig. 1) (all localities have been described 
in previous studies) (Gil et al. 2007, Tada et al. 2007, 
Katsuragawa et al. 2008, 2010): Vila Candelária (VC), 
Engenho Velho (EV), Santo Antônio (SA), Cachoeira do 
Teotônio (CT) and Vila Amazonas (VA). VC and EV are 
suburban, whereas CT and VA are rural localities ap-
proximately 30 km from the urban area. SA is at an in-
termediate distance from the urban area, with suburban 
and rural features. VC, SA and CT are accessible by road 
and regular bus service, but both EV and VA are situated 
on the left bank of the Madeira River and require boat 
transportation to access the right bank.
Population data for the five localities, which were 
provided by the municipality of Porto Velho, were ex-
trapolated from data from the National Population Cen-
sus in 2000 at the beginning of the study. A demographic 
census performed by our team updated the data. The total 
resident population of the five localities was 1,147 per-
sons. A high incidence of malaria was officially recorded 
for the previous 10 years in the five localities by the Bra-
zilian Health Ministry, with an annual parasite index of 
greater than 200 clinical cases per 1,000 inhabitants per 
year. In all of these localities, residents have access to 
malaria diagnosis and treatment in public health centres.
Study design - Preliminary definitions and data col-
lection for the study design: APCs were identified via a 
positive microscopy result, a positive PCR result in the 
absence of malaria symptoms or by clinical signs up to 
30 days following a positive result.
Clinical vivax malaria cases were classified as primary 
infections when they occurred in the follow-up population 
that previously tested negative for Plasmodium parasites 
by polymerase chain reaction (PCR). All of the clinical 
Fig. 1: study area location. The red quarters indicate the five riverine localities (CT: Cachoeira do Teotônio; EV: Engenho Velho; SA: Santo Antônio; 
VA: Vila Amazonas; VC: Vila Candelária). Madeira River is be indicated by orange colour; the green line indicates the federal highway. 
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vivax malaria cases confirmed by microscopy within 
two-four month intervals and up to one year following 
the first treated and cured episode were considered to be 
relapses. Because there are no known markers to distin-
guish a vivax re-infection from a relapse (see Discussion), 
the adopted criteria were based on the previously identi-
fied probability of acquiring a vivax infection in one year 
in these localities (Tada et al. 2007, Katsuragawa et al. 
2008, 2010); based on these probabilities, a second infec-
tion is improbable and a third infection is unlikely.
Demographic and preliminary clinical surveys - All 
of the dwellings and respective residents of the five riv-
erside communities were systematically identified. The 
dwellings were located using a Garmin eTrex VistaTM 
global positioning system device. The identity of all of 
the residents of each house, as well as their age, sex, 
socio-economic status and most important past health 
events, particularly those associated with malaria mor-
bidity, were recorded. A brief physical and clinical ex-
amination was performed by a clinician, including the 
measurement of body temperature and the presentation 
of symptoms, such as liver or spleen enlargement.
Malaria baseline cross-sectional study - For the 
malaria prevalence survey and APC identification, a 
baseline cross-sectional survey was performed in each 
of the studied localities and 5 mL of venous blood was 
collected from all residents who were at least five years 
old for the diagnosis of malaria infection, irrespective of 
the presence of clinical symptoms.
Thick blood smears were Giemsa stained and exam-
ined at 1,000X magnification and at least 100 fields were 
examined by two experienced local technicians. All posi-
tive slides and a sample of slides collected from febrile 
individuals who were considered to be negative by the lo-
cal technicians were re-examined by expert technicians 
at the Tropical Medicine Research Centre (CEPEM).
PCR was performed according to the method of 
Snounou (1996), with slight, previously described modi-
fications (Tada et al. 2007, Katsuragawa et al. 2010). 
Once identified, the asymptomatic, PCR-positive pa-
tients were systematically monitored by health agents 
(see the section on malaria surveillance below) daily for 
30 days before being considered an APC. 
Treatment of APC - The present study consisted of 
two preliminary trials conducted to examine the effect 
of treatment of APCs on the transmission dynamics of 
malaria in a locality. In the first study, in VC, one year of 
malaria surveillance (from April 2003-April 2004) was 
performed followed by a baseline cross-sectional study 
(April 2004) to identify all P. falciparum APCs. After 
the baseline cross-sectional study, all individuals that 
were PCR positive for P. falciparum were treated and 
one more year (from May 2005-May 2006) of malaria 
surveillance was performed. Detailed information about 
the malaria surveillance, the baseline cross-sectional 
study and the treatment protocol is provided in the next 
section. The data on the incidence of falciparum malaria 
during the surveillance periods before and after treat-
ment of asymptomatic P. falciparum carriers were com-
pared using the non-parametric Mann-Whitney U-test.
The second study was performed in a similar man-
ner from 2006-2008 and extended to all five localities. 
At each locality, one year of malaria surveillance was 
performed followed by a baseline cross-sectional study 
to identify all asymptomatic Plasmodium carriers. After 
the baseline cross-sectional study, 119 APCs were iden-
tified in the five localities using PCR. All 66 residents 
of EV and SA that were PCR positive for P. vivax were 
treated, whereas the 53 PCR-positive residents from VC, 
CT and VA were maintained as controls and not treated. 
One additional year of malaria surveillance was per-
formed in all five localities. Detailed information about 
the malaria surveillance, the baseline cross-sectional 
study and the treatment protocol is provided below.
The second study was designed to focus on both P. 
vivax and P. falciparum parasites. However, due to the 
reasons discussed below, only the P. vivax data could 
be confidently analysed. The data on the incidence of 
symptomatic malaria cases during the surveillance peri-
ods before and after the treatment procedures were com-
pared using the non-parametric Mann-Whitney U-test.
Malaria surveillance - At all locations, malaria sur-
veillance was conducted for at least two years: one year 
before the baseline cross-sectional study and one year 
after its completion. In both trials, the baseline survey 
was followed by one year of malaria surveillance, with 
visits to the dwellings at least five days per week. The 
inhabitants were interviewed about febrile episodes and 
every individual with a fever or any other symptoms po-
tentially related to malaria was screened for the presence 
of malarial parasites. Furthermore, a clinical and parasi-
tological examination was performed by our field team. 
Venous or finger-prick blood samples were obtained 
for the diagnosis of malaria via microscopy and PCR, 
as previously described (Tada et al. 2007, Katsuragawa 
et al. 2010). As part of the surveillance, the files of all 
patients were maintained at the two local outposts for 
malaria diagnosis. Thick blood smears were examined 
via microscopy by local technicians. All positive slides, 
a fraction of the negative slides and all of the negative 
slides from subjects presenting with fever or other po-
tential malaria symptoms were reviewed by specialised 
technicians from CEPEM. Patients identified as present-
ing with symptomatic or asymptomatic P. vivax infec-
tions were closely monitored for possible relapses.
Malaria treatment - Patients presenting with clini-
cal parasite infections were always treated according 
to the instructions in the Malaria Treatment Manual 
from the Brazilian Health Ministry (MS 2006). Qui-
nine and doxycycline were used for the treatment of 
P. falciparum infections in the first preliminary trial. 
P. vivax infections were treated with chloroquine, fol-
lowed by a short, seven-day course of primaquine (MS 
2006). Treatment was initiated within 24-48 h of the 
initiation of symptoms. The same therapeutic scheme 
recommended by the MS was used for the treatment of 
all APCs. Primaquine was used for all symptomatic and 
asymptomatic carriers, with the exception of pregnant 
women and patients with a history of allergic or toxic 
reactions to the drug.
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Parasite identification, genotyping and microsatel-
lite studies - The oligonucleotides and PCR conditions 
described by Snounou (1996) were used with slight mod-
ifications (Katsuragawa et al. 2010). Briefly, gDNA was 
amplified with primers specific for the ribosomal RNA 
genes and a second set of primers specific for P. falci-
parum, P. vivax or P. malariae. P. falciparum haplotypes 
were identified based on the size of a combination of 11 
micro-satellite loci. The gDNA samples were amplified 
using a nested PCR protocol described by Anderson et al. 
(1999). In the second reaction, one Cy5-labelled primer 
was used, allowing for the semi-automated analysis of 
the marker sizes using an ALF2 (Amersham Pharmacia) 
automated sequencer. For the analysis of the size of the 
fragments, a molecular weight marker containing a 60-
bp internal standard was added to each sample and 60-
bp, 97-bp, 175-bp and 219-bp length markers were used.
Ethical concerns - The project protocols were ap-
proved by the Ethical Research Committee of the 
CEPEM (CEP-CEPEM) of the Rondônia State Health 
Bureau and considered “scientifically and technically in 
accordance with ethical principles of conduct”. Haema-
tological and serological samples from individuals in the 
study population were collected after informed consent 
and written agreements were obtained from each indi-
vidual (CEP-CEPEM decision 25/2004).
RESULTS
First preliminary survey - Effects of the treatment 
of asymptomatic carriers on the incidence of falciparum 
malaria in VC. The first trial was performed in VC from 
April 2003-April 2005. The incidence of malaria in this 
locality was investigated by CEPEM- Research Insti-
tute In Tropical Pathologists epidemiologists. A demo-
graphic survey performed in March 2003 reported 270 
residents. The baseline survey for the identification of 
P. falciparum infections performed in March 2004 with 
223 residents who were at least five years old (82.7%) 
identified 16 P. falciparum APCs, 32 P. vivax APCs and 
three APCs with mixed infections. The 19 patients with 
P. falciparum infections were treated in May. The ma-
laria surveillance follow-up was maintained from May 
2003-April 2005 and is summarised in Fig. 2, which 
shows the monthly distribution of clinical falciparum 
malaria cases during the surveillance period.
As shown in Fig. 2, the number of clinical cases of 
falciparum malaria decreased significantly in the months 
following the treatment of the APCs in May 2004 and no 
P. falciparum episodes were recorded from May-Septem-
ber (Z = -2.39, p = 0.017). The only falciparum malaria 
case in October 2004 was an adult who arrived in VC 
with a clinical infection that had been diagnosed as fal-
ciparum malaria in another locality of RO. The previous 
microscopic examination of the thick smear performed 
on September 19 revealed the presence of P. falciparum 
gametocytes, but primaquine treatment could not be 
administered because of medical recommendations. In 
addition, four other P. falciparum cases occurred from 
November 2004-January 2005 that affected patients liv-
ing in residences near that of the imported case (2 in 
November 2004, 1 in December 2004 and 1 in January 
2005). The genotypes of the parasites collected from the 
four clinical cases, as determined using microsatellite 
analysis (Table I), were identical to that of the imported 
case and showed allelic differences from the consensus 
genotype of parasites observed in VC from 2003-2004. 
Three alleles in these four patients had not been previ-
ously found in this locality (Table I).
Second preliminary trial - Effects of the treatment 
of asymptomatic P. vivax carriers on the incidence of 
vivax malaria. This trial was initially planned for both 
P. falciparum and P. vivax APCs between 2006-2007. 
However, in mid-2007, the MS detected a clear decrease 
in the incidence of falciparum malaria throughout the 
endemic area of the Brazilian Amazon (SIVEP-Malária 
2007) that coincided with the changes in treatment 
schedules adopted by the MS. Consequently, the study 
on P. falciparum APCs was cancelled and the project 
was restricted to the effects of treating P. vivax APCs. 
Preliminary demographic surveys were developed in 
2006 in the five localities situated in the suburban and 
rural areas near the southern limit of Porto Velho (VC, 
EV, SA, CT and VA) (Fig. 1). The corresponding base-
line survey performed to identify APCs was conducted 
Fig, 2: Plasmodium falciparum cases at Vila Candelária. The malaria surveillance follow-up from September 2005-September 2007. The arrow 
indicates the treatment application. 
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progressively from July-November 2006 in the localities 
shown in Table II. PCR analysis of blood samples identi-
fied 119 P. vivax APCs among the 716 participants in the 
five localities (16.8%). Chloroquine/primaquine combi-
nation therapy was administered to 66 APC patients, 35 
from EV and 31 from SA, 30 days after the follow-up 
that confirmed an absence of symptoms in the patients. 
No treatment was administered to the other 53 APCs (23 
from VC, 18 from CT and 12 from VA). Malaria surveil-
lance was maintained for both groups for the following 
year. As shown in Fig. 3, no decrease in the incidence 
of P. vivax malaria was observed in EV in the months 
following the treatment of APCs in August 2006 (Z 
= -0.30, p = 0.762), whereas in SA, a 2.25-fold increase 
in the mean number of cases was observed (Z = -2.84, p 
= 0.005). However, it must be emphasised that the in-
crease was dependent upon data from the end of the ob-
servation period (see Discussion). In the control locali-
ties where the APCs were not treated, no decrease in the 
incidence was observed in CT (Z = -0.55, p = 0.585), 
whereas in VA, a significant decrease was observed (Z 
= -2.44, p = 0.015) (see Discussion). The follow-up of ma-
laria cases in VC suffered from a discontinuity of more 
than three months due to a failure of a health agent respon-
sible for the task and the difficulties in reorganising the 
surveillance team led us to eliminate VC from follow-up. 
These contradictory results do not allow for elucidation of 
the effect of treatment of vivax APCs (see Discussion).
Second preliminary trial - Effects of treatment of as-
ymptomatic P. vivax carriers on the frequency of vivax 
malaria relapse. The comparison of the frequency of re-
lapse in APC-treated localities (EV and SA) and untreated 
localities (VC, CT and VA) provided some unexpected re-
sults (Tables III, IV). However, there was a discontinuity 
in the follow-up of the malaria cases in VC and the data 
could not be used, as explained in the previous section. 
However, because all clinical cases were diagnosed and 
treated, a relapse register was maintained in VC. Both 
treated and untreated vivax APCs presented with an equal 
number of relapses, which were characterised by the pres-
ence of clinical symptoms and a positive microscopic 
examination during the 12 months of post-intervention 
surveillance. As seen in Table III, 21 of the 66 patients 
TABLE II
Asymptomatic malaria carrier’s prevalence in riverine localities of the Madeira River
Locality
Baseline cross section
(2006) Population
Thick smear PCR
n Pv+ Pf+ Mixed+a n Pv+ Pf+ Mixed+
Engenho Velho July 139 121 1 - - 118 35 7 5
Santo Antônio August 251 194 2 1 - 199 31 5 1
Vila Candelária September 268 205 - 1 - 205 23 3 -
Cachoeira do Teotônio November 343 119 4 - - 119 18 - -
Vila Amazonas November 144 77 - 1 - 77 12 2 -
Total - 1,147 716 7 3 - 718 119 17 6
a: Plasmodium vivax (Pv) and Plasmodium falciparum (Pf); PCR: polymerase chain reaction.
TABLE I
Comparison of micro-satellite allele sizes of Vila Candelaria’s consensus and new Plasmodium falciparum cases
Allele In the four new cases Different alleles found in previous cases Alleles not found before Alleles(n)
TAI 174 168, 171, 174, 177, 180, 183 - 6
Poly-a 182 149, 152, 155, 170, 176, 182, 185, 191 - 8
TAA60 87 75, 78, 84, 93 87 5
ARA2 66 66 - 1
Pfg377 102 96, 99 102 3
PfPK2 174 162, 171, 177 - 3
TAA87 114 93, 96, 99, 111, 114 - 4
TAA109 163 163, 166, 175 - 3
TAA81 121 115, 118, 121, 124, 127, 139 - 6
TAA42 188 188, 194, 197, 203 - 4
2490 87, 90 84, 87, 93 90 4
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(31.8%) from EV and SA that were treated for asympto-
matic infections at time zero (T0) presented with relapses 
(R1 + R2). This incidence of relapse was somewhat, but 
not significantly, greater than the incidence of relapse in 
the untreated APCs in VC, CT and VA [16 of 53 (30.2%), 
χ² = 0.134, 1 degree of freedom, p = 0.843]. Additionally, 
the difference in the overall number of clinical infections 
in the treated and untreated localities was not statistically 
significant (Z = -0.085, p = 0.933). Furthermore, over the 
same period, the frequency of relapse in patients present-
ing as PCR negative at T0 and later presenting with a clin-
ical infection that was characterised as a primary vivax 
infection in the five localities (27 in 89, 27%) was equal. 
These values fall within the range of relapse frequencies 
both reported in the literature following short-term pri-
maquine treatment (Villalobos-Salcedo et al. 2000) and ob- 
served in patients treated for clinical P. vivax infections 
residing in other localities of the study. In addition, the 
delay (in months) observed between primary infection 
and relapse was equivalent in the treated and untreated 
asymptomatic infections (Table IV). Taken together, these 
observations raise questions about the nature of NAI in P. 
vivax infections. It is important to note that the malaria 
surveillance revealed that 14 of the 51 untreated vivax 
APCs from VC, CT and VA presented with clinical epi-
sodes with positive microscopy examinations that were 
classified as relapses using the criteria adopted in this 
study (see Subjects, Materials and Methods).
DiSCUSSioN
The present study aimed to address whether treat-
ment of malaria APCs in an endemic area would de-
crease malaria transmission within the community. The 
results reported here clearly illustrate the difficulties in 
drawing conclusions from field studies. The difficulties 
in this case derive from the following independent and 
complex variables that contributed to or interfered with 
the results: (i) the nature of the protective clinical and 
anti-parasite immunity of the APCs and the distribution 
of the APCs in the community, (ii) parasite variability 
and the mechanisms used by the parasite to escape from 
the host immune response, (iii) the susceptibility of local 
parasite populations to the available anti-malarial drugs, 
(iv) the transmission capacity, seasonal density varia-
tions and efficiency of the local malaria vector, (v) the 
physical and climatic factors involved in the prolifera-
tion of the vector and (vi) demographic instability, which 
is particularly high in Brazilian Amazon communities.
Despite these difficulties, the results of the first trial 
clearly indicate a favourable effect of treating falciparum 
APCs because a significant decrease was observed in the 
local incidence of falciparum malaria in the months fol-
lowing intervention. The new falciparum malaria cases 
that appeared seven months after the intervention were 
all imported. The evaluation of the positive effect of de-
creasing the incidence was facilitated by the fact that the 
APCs were treated when no clinical cases were observed 
in the locality, indicating that the local parasite pool was 
only represented by the parasites circulating in the APCs. 
At the same time, our results show the important role of 
imported malaria in maintaining endemicity in a given 
locality. As described in the Results section, microsatel-
lite analysis (dalla-Martha et al. 2007) demonstrated that 
following treatment of the APCs, the few falciparum ma-
laria cases that were observed among the residents of the 
locality were due to the same imported parasite lineage. 
Therefore, we conclude that the benefits of treating APCs 
also require the rigorous control of imported malaria, 
which is not easily implemented in poor communities.
The evaluation of the effect of the treatment of P. 
vivax APCs provided contradictory results. Comparing 
the incidences in the 12 months preceding and follow-
ing treatment in two villages (EV and SA) with the in-
cidences in two control villages (CT and VA) where the 
APCs were not treated, we detected no variation in the 
incidences in both EV (treated APCs) and VA (untreat-
Fig. 3: incidence of Plasmodium vivax malaria in the study localities from September 2005-September 2007. APC: asymptomatic parasite 
carriers (APC).
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ed APCs). By contrast, the incidence increased in SA 
(treated APCs) and decreased in VA (untreated APCs). 
It must be noted that in the months following the inter-
vention, the SA village experienced demographic insta-
bility related to the preparation of the Santo Antônio 
hydroelectric power plant construction site. Migration, 
including the presence of hydroelectric company em-
ployees, occurred after June 2007 and this migration 
may have influenced the malaria incidence. Further-
more, in contrast with the first preliminary survey, in 
which the intervention took place when no clinical fal-
ciparum malaria cases occurred, in the second prelimi-
nary survey for P. vivax, the treatment of the APCs was 
performed when there was a high incidence of clinical 
vivax infections (Fig. 3). Therefore, the malaria sur-
veillance methodology used before and after the APC 
treatment to measure the effects on malaria transmis-
sion cannot provide a conclusive answer in the context 
of a highly endemic situation, whereas it was a useful 
method to measure transmission in lowly endemic situ-
ations (e.g., falciparum infection).
By contrast, in the surveillance of vivax malaria in 
the second preliminary survey, the follow-up of relapses 
in conjunction with APC treatment provided important 
information. However, a question that needs to be clari-
fied concerns the criteria adopted to define transmission 
dynamics by measuring relapses. In this trial, we consid-
ered primary P. vivax episodes to be infections affecting 
patients that were PCR negative in the baseline survey, 
but presented with clinical infections later. The subse-
quent clinical vivax malaria episodes that occurred in the 
same patient in the 12 months following the treatment 
and cure of the primary clinical infection were considered 
relapses. Of course, re-infections could not be excluded 
because the risk of a vivax infection in this area is nearly 
15% in one year (Tada et al. 2007). However, if one re-in-
fection within one year in the same subject is statistically 
possible, two-three subsequent re-infections are unlikely 
to occur. Using the same procedures and criteria for pa-
tients treated for asymptomatic vivax malaria infections, 
clinical infections occurring in the 12 months following 
the APC treatment were also considered relapses.
Using these criteria, some unexpected results were 
observed. Whereas primary clinical P. vivax infections 
were followed by frequent relapses, as has been described 
in studies performed in the same region (Villalobos-
Salcedo et al. 2000), surprisingly, in the 12 months fol-
lowing the intervention, both the treated and untreated 
APCs presented with one-three relapses at an equivalent 
frequency. It is important to note that relapses were only 
considered to be clinical infections following parasite 
confirmation using microscopy, which eliminates the 
possibility of recrudescence (Table IV).
In either case, even if the repetitive clinical episodes 
in the same patients are re-infections and not relapses, 
the clinical infections observed in the treated and un-
treated vivax APCs raise questions concerning the de-
velopment of naturally acquired protective anti-parasite 
immunity in P. vivax infections. Distinguishing P. vivax 
re-infections from relapses in an active endemic area 
is difficult because of the polyclonal nature of the liver 
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hypnozoites originating from the polyclonal sporozoite 
population introduced by the mosquito (Druilhe et al. 
1996, Kirchgatter & Del Portillo 1998). 
The mechanisms involved in protective immunity, ei-
ther clinical or anti-parasite, remain poorly understood for 
vivax malaria. Antibody-dependent immune responses are 
considered the basic mechanism of anti-parasite immuni-
ty in P. falciparum infections (Cohen et al. 1961, Fandeur 
et al. 1984, Bouharoum-Tavoun et al. 1990, Groux et al. 
1990, Gysin et al. 1992). However, no equivalent obser-
vations are available for P. vivax and how anti-parasite 
immunity develops against P. vivax remains poorly un-
derstood. Our results are in agreement with those of Col-
lins and Jeffery (1999), who reported on the retrospec-
tive examination of sporozoite and trophozoite-induced 
infections in neurosyphilitic patients treated with vivax 
malaria therapy (Camargo et al. 1999, Alves et al. 2002). 
They found that the development of anti-parasite immuni-
ty is variant specific. In conclusion, if the treatment of P. 
vivax APCs is proposed with the aim of interfering with 
P. vivax transmission by reducing the pool of parasites, 
the results of the present study indicate that this interven-
tion would likely have no practical value. As APCs infect 
the vector less efficiently (Alves et al. 2005), but present 
with frequent symptomatic relapses or re-infections with 
higher parasitaemia, treatment of APCs would have mi-
nor consequences for malaria transmission.
Molecular tests are not widely used in the diagnosis 
of malaria in the general public. However, in the present 
study and in eventual future studies, a preliminary sur-
vey by PCR was or should be performed only once at the 
beginning of the intervention followed by surveillance 
using microscopy for diagnosis. In eradication programs, 
the procedure could be performed in nearby localities, 
individually. The role of APCs in malaria transmission 
has been and remains the subject of discussion by experts 
worldwide and there is still no consensus. In the present 
study, we conclude that there is not one single answer to 
the question. Our results show that the treatment of falci-
parum APCs has a positive effect on decreasing falcipar-
um malaria transmission in one locality. However, this 
was observed in a locality with a relatively low prevalence 
of falciparum malaria and also depended on strong sur-
veillance to prevent re-introduction of imported malaria 
by visitors and/or the arrival of new residents harbouring 
the parasite. With respect to vivax malaria, our results 
show that when using a short course of primaquine, the 
frequency of relapse is high and therefore, the treatment 
of vivax APCs would have practically no effect on ma-
laria transmission. In addition, is not possible to use a 
14-day primaquine treatment on vivax APCs, which does 
not completely eliminate relapses (Villalobos-Salcedo 
et al. 2000). Therefore, we conclude that the treatment 
of vivax APCs is not useful. However, if new drugs are 
discovered with activity against hypnozoites or if other 
methods to avoid relapses are developed, the treatment of 
vivax APCs may be useful.
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